C1q protilátky a součást komplementu odrážejí aktivitu SLE a postižení ledvin

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F06%3A00003142" target="_blank" >RIV/61989592:15110/06:00003142 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

C1q complement component and antibodies reflect SLE activity and kidney involvement

Popis výsledku v původním jazyce

The role of the complement systém in the pathogenesis of systemic diseases is very ambivalent. In systemic lupus erythematosus (SLE), many abnormalities in the activation of the complement systém have been reported. The most important antibodies formed against the complement systém in SLE are the ones associated with the C1q component. The aim of this study was to assess separately the anti-C1q antibodies and C1q component in the serum from 65 patients with SLE, then in individuals with (n=33) and without (n=32) lupus nephritis and with active n=36) and nonactive (n=29) form of the disease (European Consensus Lupus Activity Measurement, ECLAM>3, ECLAM&#8804;3). This study also aims to look for correlations with other clinical and laboratory parameters.The C1q antibodies were measured by the Enzyme-Linked Immunosorbent Assay (ELISA) test, while radial immunodiffusion according to Mancini was used to measure the C1q complement component. The mean serum levels were 90.89+/-13 IU/ml for a

Název v anglickém jazyce

C1q complement component and antibodies reflect SLE activity and kidney involvement

Popis výsledku anglicky

The role of the complement systém in the pathogenesis of systemic diseases is very ambivalent. In systemic lupus erythematosus (SLE), many abnormalities in the activation of the complement systém have been reported. The most important antibodies formed against the complement systém in SLE are the ones associated with the C1q component. The aim of this study was to assess separately the anti-C1q antibodies and C1q component in the serum from 65 patients with SLE, then in individuals with (n=33) and without (n=32) lupus nephritis and with active n=36) and nonactive (n=29) form of the disease (European Consensus Lupus Activity Measurement, ECLAM>3, ECLAM&#8804;3). This study also aims to look for correlations with other clinical and laboratory parameters.The C1q antibodies were measured by the Enzyme-Linked Immunosorbent Assay (ELISA) test, while radial immunodiffusion according to Mancini was used to measure the C1q complement component. The mean serum levels were 90.89+/-13 IU/ml for a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8406" target="_blank" >NR8406: Prognostický význam přítomnosti hypokomplementemie pro typ a klinickou manifestaci lupusové glomerulonefritidy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Rheumatology

ISSN

0770-3198

e-ISSN

—

Svazek periodika

25

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

BE - Belgické království

Počet stran výsledku

5

Strana od-do

532-536

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—